Week

Future Celebrates Market Leading Position As Largest Tech News Publisher

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Digital publishing powerhouse Future Publishing has been the worlds leading consumer technology publisher for the past 12 months, following the growth of its flagship tech sites.

Key Points: 
  • NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Digital publishing powerhouse Future Publishing has been the worlds leading consumer technology publisher for the past 12 months, following the growth of its flagship tech sites.
  • Every year Future attracts hundreds of millions of consumers to its websites, print magazines, events, and social channels.
  • Future is now home to some of the worlds most-loved media brands: CinemaBlend, Wallpaper*, PC Gamer, and more.
  • *Source: Comscore, Media Metrix, multi-platform, Future Plc Total Audience July 2022, US
    Future is a global multi-platform media company and leading digital publisher, with scalable brands and diversified revenue streams.

Blenders Eyewear Announces Partnership with Los Angeles Rams Football Safety Taylor Rapp

Retrieved on: 
Thursday, September 22, 2022

SAN DIEGO, Sept. 22, 2022 /PRNewswire/ -- Blenders Eyewear, a part of the Safilo Group, one of the eyewear industry's key players, announced today an exciting new partnership with football safety of the Los Angeles Rams, Taylor Rapp. Through this exciting new partnership, Rapp marks the newest addition to the company's quickly growing athlete roster and will serve as an official brand ambassador.

Key Points: 
  • SAN DIEGO, Sept. 22, 2022 /PRNewswire/ -- Blenders Eyewear ,a part of the Safilo Group, one of the eyewear industry's key players, announced today an exciting new partnership with football safety of the Los Angeles Rams, Taylor Rapp.
  • "Taylor is incredibly talented on the football field, and off the field, he's a positive role model," said Christian Scott, Vice President of Marketing at Blenders Eyewear.
  • This exciting new partnership with Rapp is the brand's second NFL player and extends Blenders Eyewear's impressive roster of leading athletes.
  • Blenders Eyewear was founded in 2012 by Fisher in San Diego, California and manufacturers sunglasses, snow goggles and prescription eyewear.

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

Retrieved on: 
Thursday, September 22, 2022

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

Key Points: 
  • VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial.
  • Chronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV).
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.

Greenberg Traurig's Mathew Rosengart Receives Multiple Honors; Introduced by Former US Supreme Court Justice David H. Souter

Retrieved on: 
Wednesday, September 21, 2022

LOS ANGELES, Sep. 21, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP Shareholder Mathew S. Rosengart was named to the Daily Journal's 2022 Top 100 Lawyers list. In addition, the Beverly Hills Bar Association (BHBA) is honoring Rosengart with the Excellence in Advocacy Award at its 10th Annual Litigation Dinner Sept. 21 at The Maybourne Beverly Hills hotel.

Key Points: 
  • Global law firm Greenberg Traurig, LLP Shareholder Mathew S. Rosengart was named to the Daily Journal's 2022 Top 100 Lawyers list.
  • LOS ANGELES, Sep. 21, 2022 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP Shareholder Mathew S. Rosengart was named to the Daily Journal's 2022 Top 100 Lawyers list.
  • "The Beverly Hills Bar Association is pleased to recognize Mathew S. Rosengart and Judge David J. Cowan for their far-reaching impact in our legal profession," BHBA President Anthony D. Ross said in a statement.
  • Retired Supreme Court Justice David H. Souter, for whom Rosengart clerked on the Supreme Court of New Hampshire and who has lauded Rosengart's intellect, instinct, and personal integrity, is scheduled to introduce him at the dinner.

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
Wednesday, September 21, 2022

Preclinical data on BI 456906 will also be presented at the EASD annual meeting.

Key Points: 
  • Preclinical data on BI 456906 will also be presented at the EASD annual meeting.
  • BI 456906 is being developed by Boehringer Ingelheim and was co-invented with Zealand Pharma.
  • Most adverse events were reported during the dose-escalation phase of the trial, and therefore slower escalation schemes may mitigate the frequency.
  • Different doses of BI 456906 were escalated every 12 weeks to ensure that 10 weeks were spent on a maintenance dose.

National Lacrosse League Announces 2022-23 Schedule; Face Off Weekend Set for December 2-3

Retrieved on: 
Tuesday, September 20, 2022

Philadelphia, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The National Lacrosse League (@NLL) today announced the largest schedule in its history 135 games as the 2022-23 regular season gets underway with Face Off Weekend on December 2-3, 2022.

Key Points: 
  • Philadelphia, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The National Lacrosse League (@NLL) today announced the largest schedule in its history 135 games as the 2022-23 regular season gets underway with Face Off Weekend on December 2-3, 2022.
  • Face Off Weekend will include two TSN Game of the Week contests on Friday, December 2 (Philadelphia Wings at Halifax Thunderbirds, 6 p.m.
  • The complete national broadcast schedules for TSN and ESPN and the Leagues playoff schedule will be announced in the coming weeks.
  • The National Lacrosse League (NLL) is North America's premier professional lacrosse league.

Designmodo Releases Siter.io, Cloud-Based, No-Code Website Builder

Retrieved on: 
Monday, September 19, 2022

NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Designmodo , a company known for website design and development tools, announced the release of Siter.io , a no-code website builder that allows users to design directly in the browser.

Key Points: 
  • NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Designmodo , a company known for website design and development tools, announced the release of Siter.io , a no-code website builder that allows users to design directly in the browser.
  • The website community has responded positively to the product with #1 Product of the Day and #1 Product of the Week honors on Product Hunt.
  • "We're thrilled at the response to Siter.io and are encouraged to continue to build more features into the product," said Andrian Valeanu, founder of Designmodo.
  • "Having a freehand site builder that you can use without code makes website design more accessible to all."

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Retrieved on: 
Monday, September 19, 2022

The Virios Therapeutics team received unblinded data relating to the FORTRESS study on Friday, September 16, 2022.

Key Points: 
  • The Virios Therapeutics team received unblinded data relating to the FORTRESS study on Friday, September 16, 2022.
  • Virios Therapeutics will host a conference call and live webcast to discuss the FORTRESS study results today, Monday, September 19th, at 8:30 a.m. Eastern Time.
  • A live webcast and replay of the call will also be available on the Virios Therapeutics, Inc. website at www.virios.com .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

Retrieved on: 
Monday, September 19, 2022

DAXXIFY demonstrated long-lasting efficacy in all subgroups, consistent with the overall population results of the SAKURA clinical trials.

Key Points: 
  • DAXXIFY demonstrated long-lasting efficacy in all subgroups, consistent with the overall population results of the SAKURA clinical trials.
  • Efficacy and safety were analyzed by age (18-45, >45-55, and >55 years) and race (Asian, Black/African American, and White).
  • DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study.
  • A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study.

Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial

Retrieved on: 
Monday, September 19, 2022

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the last patients completed their final (3-month) visit in the Mont Blanc Phase 3 clinical trial of NCX 470 0.1% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the last patients completed their final (3-month) visit in the Mont Blanc Phase 3 clinical trial of NCX 470 0.1% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • NCX 470 has the potential to be a best-in-class glaucoma treatment, and we look forward to sharing the topline results in early November.
  • Mont Blanc is a multi-regional, double-masked, 3-month, parallel group trial evaluating the efficacy and safety of NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution, 0.005%.
  • The second Phase 3 trial on NCX 470, Denali, is being jointly conducted and equally financed with our Chinese partner, Ocumension Therapeutics.